Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,612 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,612 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $18.11, for a total value of $119,743.32. Following the completion of the transaction, the director directly owned 365,273 shares of the company’s stock, valued at $6,615,094.03. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Maplight Therapeutics Trading Down 4.8%

NASDAQ:MPLT opened at $17.69 on Friday. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $21.55. The firm has a market cap of $802.60 million and a P/E ratio of -0.48. The stock’s 50 day simple moving average is $17.62.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Morgan Stanley assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They set an “overweight” rating and a $34.00 target price on the stock. Jefferies Financial Group started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective on the stock. Weiss Ratings assumed coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. Leerink Partners initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “outperform” rating and a $30.00 price target for the company. Finally, Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.